A.R.T. Advisors’s Theriva Biologics TOVX Stock Holding History

A.R.T. Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-7	Closed	-$39K	–	1718
2017 Q1	$39K	Buy	+7	New	+$48.8K	﹤0.01%	1343
2014 Q3	–	Sell	-12	Closed	-$180K	–	1526
2014 Q2	$180K	Buy	+12	New	+$190K	0.01%	1155

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

A.R.T. Advisors's TOVX Position: Q2 2017 in Review

A.R.T. Advisors sold out of Theriva Biologics (TOVX) in Q2 2017, closing a stake of 7 shares — an estimated $39K sold.

A.R.T. Advisors first reported a position in TOVX in Q2 2014 and held it in 2 quarters. The position peaked at $180K in Q2 2014. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

A.R.T. Advisors reported no remaining Theriva Biologics position as of Q2 2017 after selling out during the quarter.
A.R.T. Advisors sold 7 Theriva Biologics shares in Q2 2017, an estimated $39K.
A.R.T. Advisors first reported a position in Theriva Biologics in Q2 2014 and held it in 2 quarters.
A.R.T. Advisors's Theriva Biologics position peaked at $180K in Q2 2014.
53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on A.R.T. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.